-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

CAR T-Cell Therapy in Aggressive Lymphomas-Identifying Prognostic and Predictive Markers

Program: Education Program
Session: How Do We Calibrate Cellular Therapy for Lymphoma in 2023?
Hematology Disease Topics & Pathways:
Lymphomas, non-Hodgkin lymphoma, B Cell lymphoma, Diseases, indolent lymphoma, aggressive lymphoma, Therapies, Lymphoid Malignancies
Saturday, December 9, 2023, 9:30 AM-10:45 AM

Anna Maria Sureda Balari, MD, PhD

Clinical Hematology Department, Institut Català d'Oncologia-L'Hospitalet, IDIBALL, Universitat de Barcelona, Barcelona, Spain

Disclosures: Sureda Balari: Astra Zeneca: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; MSD: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Kite: Consultancy, Honoraria.

Previous Presentation | Next Presentation >>